Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
Maria Stefania InfanteAna Fernández-CruzLucia NúñezCecilia CarpioAna Jiménez-UbietoJavier López-JiménezLourdes VásquezRaquel Del CampoSamuel RomeroCarmen AlonsoDaniel MorilloMargarita PratJosé Luis PlanaPaola VillafuerteGabriela BastidasAna BocanegraÁngel SernaRodrigo De NicolásJuan MarquetCarmen Mas-OchoaRaúl CordobaJulio García-SuárezAlessandra ComaiXavier MartínMariana Bastos-OreiroCristina SeriBelén Navarro-MatillaArmando López-GuillermoJoaquín Martínez-LópezJosé Ángel Hernández-RivasIsabel Ruiz-CampsCarlos Grandenull nullPublished in: Cancer medicine (2021)
A high proportion of patients presented severe infections during follow-up, with non-negligible attributable mortality, but infection incidence is not superior to the one observed during the chemotherapy era. In selected cases with specific risk factors for infection, antimicrobial prophylaxis should be considered.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- risk factors
- early onset
- chronic kidney disease
- staphylococcus aureus
- prognostic factors
- peritoneal dialysis
- cardiovascular events
- drug induced
- cardiovascular disease
- patient reported outcomes
- locally advanced
- coronary artery disease
- patient reported
- diffuse large b cell lymphoma